A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

NCT01239017 PHASE2 WITHDRAWN

This is a double-blind, prospective, randomized study in which patients will be randomized to 1 of 5 treatment arms (4 active and 1 placebo). Each patient will receive one SC injection of REGN475 or placebo and 1 IV infusion of either REGN475 or placebo, on day 1 (baseline) In order to preserve the blind, patients receiving REGN475 SC will also receive placebo IV, and patients receiving REGN475 IV will also receive placebo SC.

Details

Lead sponsor	Regeneron Pharmaceuticals
Phase	PHASE2
Status	WITHDRAWN

Conditions

• Osteoarthritis

Interventions

• REGN475
• Placebo